A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)

被引：2

作者：

Andre, F. ^{[1
]}

Kaufman, B. ^{[2
]}

Juric, D. ^{[3
]}

Ciruelos, E. ^{[4
]}

Iwata, H. ^{[5
]}

Mayer, I. A. ^{[6
]}

Conte, P. ^{[7
]}

Rugo, H. S. ^{[8
]}

Loibl, S. ^{[9
]}

Rubovszky, G. ^{[10
,11
]}

Tesch, H. ^{[12
]}

Inoue, K. ^{[13
]}

Lu, Y-S. ^{[14
]}

Ryvo, L. ^{[15
]}

Longin, A-S. ^{[16
]}

Mills, D. ^{[16
,17
]}

Wilke, C. ^{[17
]}

Germa, C. ^{[18
]}

Campone, M. ^{[19
]}

机构：

[1] Inst Gustave Roussy, Dept Med Oncol, Breast Canc Unit, Villejuif, France

[2] Chaim Sheba Med Ctr, Breast Canc Unit, Ramat Gan, Israel

[3] Massachusetts Gen Hosp, Termeer Ctr Targeted Therapies, Boston, MA 02114 USA

[4] Univ Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain

[5] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi, Japan

[6] Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN USA

[7] Univ Padua, Ist Oncol Veneto IRCCS, Padua, Italy

[8] Univ Calif San Francisco, Ctr Comprehens Canc, Med Hematol Oncol, San Francisco, CA 94143 USA

[9] German Breast Grp, Med & Res, Neu Isenburg, Germany

[10] Natl Inst Oncol, Internal Med Oncol Div B, Budapest, Hungary

[11] Natl Inst Oncol, Dept Clin Pharmacol, Budapest, Hungary

[12] Ctr Hamatol & Onkol Bethanien, Dept Oncol, Frankfurt, Germany

[13] Saitama Canc Ctr, Div Breast Oncol, Saitama, Japan

[14] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[15] Tel Aviv Sourasky Med Ctr Ichilov, Div Oncol, Tel Aviv, Israel

[16] Novartis Pharma SAS, Paris, France

[17] Novartis Pharma AG, Basel, Switzerland

[18] Novartis Pharmaceut, E Hanover, NJ USA

[19] Ctr Rene Gauducheau, Med Oncol, Inst Cancerol Ouest Site, St Herblain, France

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw365.90

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

311TiP

引用

页数：1

共 50 条

[1] SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy
Andre, F.
Kaufman, B.
Juric, D.
Ciruelos, E. M.
Iwata, H.
Mayer, I. A.
Rugo, H. S.
Conte, P.
Liobl, S.
Rubovszky, G.
Inoue, K.
Tesch, H.
Lu, Y-S
Ryvo, L.
Longin, A-S
Mills, D.
Wilke, C.
Germa, C.
Campone, M.
CANCER RESEARCH, 2017, 77
[2] A phase III study of alpelisib and fulvestrant for hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
Iwata, H.
Rubovszky, G.
Loibl, S.
Ciruelos, E.
Campone, M.
Juric, D.
Rugo, H.
Mayer, I.
Conte, P. F.
Kaufman, B.
Inoue, K.
Tesch, H.
Li, Y-S.
Mingorance, I. D.
Ryvo, L.
Iwase, H.
Longin, A-S.
Mills, D.
Wilke, C.
Andre, F.
ANNALS OF ONCOLOGY, 2016, 27
[3] A phase 3 study of alpelisib (ALP) plus fulvestrant (FUL) in men and postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) ABC progressing on or after aromatase inhibitor (AI) therapy: SOLAR-1
Rugo, Hope S.
Andre, Fabrice
Rubovszky, Gabor
Kaufman, Bella
Inoue, Kenichi
Takahashi, Masato
Shimizu, Satoru
Ciruelos, Eva M.
Campone, Mario
Conte, Pier Franco
Iwata, Hiroji
Loibl, Sibylle
Mayer, Ingrid A.
Juric, Dejan
Longin, Anne-Sophie
Mills, David
Wilke, Celine
Sellami, Dalila B.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[4] ECONOMIC ANALYSIS OF COMBINATION THERAPY WITH ALPELISIB AND FULVESTRANT FOR TREATMENT OF HORMONE RECEPTOR-POSITIVE (HR plus ) AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER
Delevry, D.
Le, Q. A.
VALUE IN HEALTH, 2020, 23 : S32 - S33
[5] Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) plus fulvestrant (FUL) for hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC)
Andre, F.
Ciruelos, E. M.
Juric, D.
Loibl, S.
Campone, M.
Mayer, I.
Rubovszky, G.
Yamashita, T.
Kaufman, B.
Lu, Y-S.
Inoue, K.
Papai, Z.
Takahashi, M.
Ghaznawi, F.
Mills, D.
Kaper, M.
Miller, M.
Conte, P. F.
Iwata, H.
Rugo, H. S.
ANNALS OF ONCOLOGY, 2020, 31 : S1150 - S1151
[6] SOLAR-1: A phase III study of alpelisib plus fulvestrant in men and postmenopausal women with HR+/FIER2-dvanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy.
Andre, Fabrice
Campone, Mario
Ciruelos, Eva M.
Iwata, Hiroji
Loibl, Sibylle
Rugo, Hope S.
Wilke, Celine
Mills, David
Chol, Marie
Longin, Anne-Sophie
Juric, Dejan
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[7] THE ALPELISIB (ALP) EXPERIENCE IN THE SOLAR-1 AND BYLIEVE STUDIES: PERSPECTIVES FOR PRACTITIONERS CARING FOR PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC)
Rugo, Hope S.
Andre, Fabrice
Park, Yeon Hee
Drullinsky, Pamela
Loibl, Sibylle
Cardoso, Fatima
Mason, Ginny
Aubel, Dawn
Lorenzo, Ines
Akdere, Murat
Ciruelos, Eva M.
BREAST, 2021, 59 : S49 - S49
[8] Patients' preferences for postmenopausal hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer treatments in Japan
Omori, Y.
Enatsu, S.
Cai, Z.
Ishiguro, H.
CANCER RESEARCH, 2019, 79 (04)
[9] Alpelisib (ALP) plus fulvestrant (FUL) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study.
Juric, Dejan
Rugo, Hope S.
Reising, Albert
Ma, Chong
Ciruelos, Eva M.
Loibl, Sibylle
Singer, Christian F.
Sohn, Joohyuk
Campone, Mario
Conte, Pierfranco
Iwata, Hiroji
Ghaznawi, Farhat
Miller, Michelle Kristine
Taran, Tetiana
Su, Fei
Andre, Fabrice
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[10] BYLieve: A phase 2 study of alpelisib with fulvestrant or letrozole for treatment of PIK3CA mutant, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase (CDK)4/6 inhibitor therapy
Rugo, Hope S.
Turner, Nicholas
Chia, Stephen
Ciruelos, Eva
Nienstedt, Carolyn
Ridolfi, Antonia
Kong, Oliver
Sankaran, Banu
Juric, Dejan
CANCER RESEARCH, 2018, 78 (04)

← 1 2 3 4 5 →